The MM&M Podcast 5.29.2019: inThought Research’s Michelle Rivera
inThought Research analyst Michelle Rivera speaks with MM&M about the pathophysiology of the disease spinal muscular atrophy (SMA), the SMA drug pipeline, and how payers may react expensive drugs.
Novartis gene therapy gets green light, and a price tag of $2.1 million
The 2019 pipeline report: Changing the treatment paradigm
Are today’s developmental drugs tomorrow’s blockbusters? MM&M surveys what’s ahead for top candidates in six therapeutic categories.
Promising rare conditions treatments could upend the market hierarchy
With less than 14% of Phase I to III drug candidates winning FDA approval, unforeseen roadblocks can derail even the most promising clinical research programs.
Orphan drugs leveraging new tech promise to cure disease
Did the market overreact to Biogen’s Alzheimer’s data?
The 2018 pipeline report: Aspiring assets to keep an eye on
The immuno-oncology market prepares for the inevitable question: ‘What’s next?’
